Document is current
Any future updates will be listed below
-
Authors
,
Boscarino, Joseph A.
Moorman, Anne C.
Rupp, Loralee B.
Zhou, Yueren
Lu, Mei
Teshale, Eyasu H.
Gordon, Stuart C.
Spradling, Philip R.
Schmidt, Mark A.
Trinacty, Connie Mah
Zhong, Yuna
Holmberg, Scott D.
Holtzman, Deborah
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention
- License Information
-
More Information
Article History
Received: 9 February 2017
Accepted: 7 August 2017
First Online: 6 September 2017
Compliance with ethical standards
:
: Stuart C. Gordon receives grant/research support from AbbVie Pharmaceuticals, Bristol-Myers Squibb, Conatus, CymaBay, Exalenz BioScience, Gilead Pharmaceuticals, GlaxoSmithKline, Intercept Pharmaceuticals, and Merck, and Vertex Pharmaceuticals. He is also a consultant/advisor for Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb, CVS Caremark, Gilead Pharmaceuticals, Intercept, Merck, and Novartis, has served on the Data Monitoring Board for Tibotec/Janssen Pharmaceuticals, has served as a speaker/teacher in programs sponsored by Gilead Pharmaceuticals and Intercept Pharmaceuticals. The other authors have no potential conflicts of interest.
: The investigation followed the guidelines of the US Department of Health and Human Services regarding protection of human subjects. The study protocol was approved and renewed annually by each participating institution’s institutional review board.
